scholarly journals Vestibular Neuritis in Patients among Different Age Groups: Clinical Features and Outcomes

2020 ◽  
Author(s):  
Tao Yan ◽  
Fangru Zong ◽  
Xiao Han ◽  
Xiaojing Wang ◽  
Qiuhong Li ◽  
...  
Keyword(s):  
Clinical Features ◽  
Age Groups ◽  
Vestibular Neuritis ◽  
Anxiety And Depression ◽  
Sign Test ◽  
Adolescent Group ◽  
Younger Patients ◽  
Perceived Disability ◽  
Significant Difference ◽  
Caloric Response

Abstract Background Patients with vestibular neuritis (VN) displayed differential prognosis despite of the same treatment. Thus, identifying unique characteristics in different populations and creating individually customized treatments are necessary. However, studies about the clinical features according to different ages are scarce. Purpose This article compares the differences in VN patients among different age groups. Research Design A prospective study. Study Sample A total of 70 VN patients were enrolled in the present study. Intervention All the patients started vestibular rehabilitation at the time of initial presentation to our clinic. They were followed up at 1-month intervals using the questionnaire until 4 months. Data Collection and Analysis Patients' clinical data including clinical presentation, vestibular testing results, treatment, and recovery was collected and analyzed with Duncan's multiple range test, the sign test, and the Kruskal–Wallis test using SPSS18.0. Results The mean age of the 70 patients was 47.2 ± 17.1, ranging from 10 to 76 years old. The sex ratios (male:female) were 3.5 in the adolescent group, 0.643 in the young adult group, 1.375 in the middle-aged group, and 0.583 in the senior group. The prevalence of hypertension and diabetes mellitus showed a significantly increasing trend from young adults to the seniors (p < 0.05). The caloric response was statistically worse in the senior group than the other groups (p < 0.05). The abnormal rates for video head impulse test, vestibular-evoked myogenic potential, and vestibular autorotation test did not differ significantly in different age groups. A significant difference between prerehabilitation and postrehabilitation total Dizziness Handicap Inventory (DHI) scores was identified in all the groups (p < 0.05). The younger patients demonstrated a greater improvement than patients in the senior group, meanwhile adolescents improved the most (p < 0.05). Hospital Anxiety and Depression Scale (HADS) was the lowest in the adolescent group (p < 0.05). DHI score at acute stage was significantly correlated with HADS (r = 0.597, p < 0.05). Conclusion The canal response was statistically better for younger patients compared with the elderly. The younger patients demonstrated a greater improvement than patients in the senior group, among whom adolescents improved the most, meanwhile psychological factors played a minor role in adolescents. Self-perceived disability-handicap positively correlated with anxiety and depression in all patients.

scholarly journals Older Patients Are Less Affected by Radiochemotherapeutic Treatment than Younger

2018 ◽  
Vol 2018 ◽  
pp. 1-8
Author(s):  
Max J. Weiling ◽  
Wencke Losensky ◽  
Katharina Wächter ◽  
Teresa Schilling ◽  
Fabian Frank ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Elderly Patients ◽  
Cancer Patients ◽  
Older Patients ◽  
Normative Data ◽  
Age Groups ◽  
German Population ◽  
Younger Patients ◽  
Significant Difference

Purpose. The general assumption is that cancer therapy impairs the quality of life in elderly patients more than in younger ones. We were interested in the effects of radiochemotherapeutic treatment on the quality of life of elderly patients compared to younger patients and compared to normative data of a general German population. Methods and Materials. A total of 465 patients completed the EORTC QLQ-C30 questionnaire. Repetitive completion of the questionnaire over time led to 1407 datasets. Our patient cohort contained 197 (42.4%) patients with colorectal cancer followed by 109 (23.4%) patients with head and neck cancer, 43 (9.2%) patients with lung cancer, and 116 (25%) with other types of cancer. Patients were categorized into five age groups, the respective cut-offs being 40, 50, 60, and 70 years. Normative data were drawn from a population study of a general German population. Results. Functional scores and symptom scores were approximately stable between the different age groups. Our data does not suggest a significant difference between the investigated age groups. Advancing age evened out the differences between the normative data of the general German population and the cancer patients in 11 of 15 scores. Conclusions. The general belief about younger patients having fewer physical and psychological problems related to radiochemotherapy needs to be reconsidered. Overall resilience of older patients is apparently underestimated.

Unrelated Cord Blood Transplantation Using Myeloablative Regimen for Acute Leukemia Patients Aged between 50 and 55 Years: Single Institutional Retrospective Comparison with Patients Less Than 50 Years of Age.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2013-2013
Author(s):  
Takaaki Konuma ◽  
Satoshi Takahashi ◽  
Jun Ooi ◽  
Akira Tomonari ◽  
Nobuhiro Tsukada ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Cord Blood ◽  
Older Patients ◽  
Acute Gvhd ◽  
Cord Blood Transplantation ◽  
Chronic Gvhd ◽  
Age Groups ◽  
Younger Patients ◽  
Cell Dose ◽  
Significant Difference

Abstract Background: Increasing age has been well-known as an obvious risk factor for graft-versus-host disease (GVHD) and transplant-related mortality (TRM) resulting negative impact on allogeneic transplantation including cord blood transplant (CBT). The incidence of sever GVHD after CBT, on the other hand, is lower than that after transplants using graft from adult cells, so we have expected the better results of CBT in older patients. Objectives and Methods: This study aimed to evaluate safety and efficacy of CBT using myeloablative regimen for older patients with acute leukemia. Patients and Methods: We retrospectively compared outcomes of older patients with acute leukemia with younger adults in our institute. Nineteen elderly patients (median age 52, range 50–55) and 81 young patients (median 49, range 16–49) received myeloablative conditioning regimen including 12 Gy of total body irradiation. GVHD prophylaxis comprised cyclosporine with (N=96) or without (N=4) methotrexate. Results: Comparisons of characteristics in the 2 age groups showed similar distributions for weight, gender ratio, diagnosis [de novo acute myeloid leukemia (AML), myelodysplastic syndrome related secondary AML, or acute lymphoblastic leukemia], disease status at transplantation, total nucleated cell dose and CD34+ cell dose in the graft before cryopreservation and proportions of HLA and sex compatibility between donors and recipients. The median period of follow-up for survivors after CBT was 730 days for older group and 1331 days for younger group, respectively. Grade II to IV acute GVHD occurred in 10 of 17 evaluable older patients and 49 of 75 evaluable younger patients (P = 0.61), while no older patients, but 6 younger patients developed grade III to IV acute GVHD. Extensive-type chronic GVHD occurred in 4 of 15 evaluable older patients and 18 of 69 evaluable younger patients (P = 0.96), respectively. The cumulative incidence of TRM at 100 days was 5% versus 6% (P = 0.70), and of relapse at 3 years was 29% versus 20% (P = 0.33) and the estimated disease-free survival at 3 years was 67% and 71% (P = 0.53) for older or younger patients, respectively. There was no significant difference in GVHD, TRM, relapse, and DFS between 2 age groups. Conclusion: The use of cord blood as a stem cell source might contribute to be decreased in the incidence of acute and chronic GVHD resulting in decreased TRM in older patients. Our results suggest that myeloablative CBT might be as safe and effective in patients with acute leukemia aged between 50 and 55 years as in younger patients.

Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1378-1378
Author(s):  
Deborah M Stephens ◽  
Amy S. Ruppert ◽  
Kristie A. Blum ◽  
Jeffrey A. Jones ◽  
Joseph M. Flynn ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Kinase Inhibitor ◽  
Single Agent ◽  
Age Groups ◽  
Lymphocytic Leukemia ◽  
Cyclin Dependent Kinase ◽  
Complex Karyotype ◽  
Younger Patients ◽  
Cyclin Dependent Kinase Inhibitor ◽  
Significant Difference

Abstract Abstract 1378 Although the most rapidly growing portion of the United States population is the elderly (Yancik R and Ries L, Semin Oncol 2004), they are consistently underrepresented in cancer clinical trials (Hutchins L et al, N Engl J Med 1999). The incidence of chronic lymphocytic leukemia (CLL) is markedly increased in older people, with a median age at diagnosis of 72 years (Ries L et al, SEER Clinical Statistics Review 2008). In contrast, an age range of between 58 and 66 years has been noted in patients (pts) enrolled in key trials to evaluate the first-line treatment for CLL (Eichhorst B et al, Leuk Lymphoma 2009). Both fludarabine and chemoimmunotherapy with rituximab have not demonstrated much promise in the older subset of patients. Developing new therapeutics that have clinical benefit and also demonstrate feasibility of administration to this patient population is of great interest. Flavopiridol, is a pan-cyclin-dependent kinase inhibitor, that has demonstrated significant clinical activity in relapsed and refractory CLL pts including those with del(17p13.1)(Christian B et al, Clin Lymphoma Myeloma 2009). We sought to determine the feasibility and impact of treating patients over the age of 70 with flavopiridol by reviewing outcomes of two clinical trials using single-agent flavopiridol in patients with relapsed or refractory CLL at our institution (Byrd J et al, Blood 2007; Lin T et al, J Clin Oncol 2009). Pts were divided into categories based on age [≥70 years old (n = 21) and <70 years old (n = 95)]. Of the 21 pts aged 70 or older, all but one (95%) presented with Rai Stage III/IV compared with 76% of the younger pts (<70 years old; P = 0.07). Older age was also associated with complex karyotype (63% vs. 37%; P = 0.04). No significant difference was observed in response rates, with 43% of older pts achieving response vs. 47% of younger pts (P = 0.81). The estimated median progression free survival (PFS) for both age groups was 0.8 years (P = 0.9). In multivariable analyses, there remained no significant differences in response rates or PFS when controlling for treatment schedule, Rai stage and presence of complex karyotype (P = 0.76 and P = 0.89, respectively). Although overall survival tended to be worse in the older pts compared with the younger pts (estimated medians of 2.1 and 2.4 years, respectively), following adjustment for other variables in a multivariable analysis, this difference was no longer significant (P = 0.54, hazard ratio = 1.20 [95% CI: 0.7 – 2.1]). With respect to toxicities, no significant difference in occurrence of tumor lysis syndrome (TLS) or cytokine release syndrome (CRS) was observed between the two age groups, TLS occurred in 48% of older pts and 45% of younger pts (P = 1.00), while CRS occurred in 33% of older pts and 36% of younger pts (P = 1.00). As for infection, only 29% of older pts experienced this toxicity compared to 62% of younger pts (P = 0.007). In multivariable pharmacokinetic (PK) analyses of a patient subset (n=56), there were no significant associations observed between PK parameters and age when controlling for age, bilirubin level, alanine transaminase level, platelet count, white blood cell count, BUN, and 14 distinct single nucleotide polymorphisms. These data demonstrate that flavopiridol administration to older CLL patients is both feasible, acceptably tolerated, and has similar efficacy as compared to younger patients. Future development of treatment approaches with both single-agent and combination strategies of flavopiridol should be considered for older CLL patients. Disclosures: Off Label Use: The efficacy of the cyclin dependent kinase inhibitor, flavopiridol is under investigation in CLL. Jones:GlaxoSmithKline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbott Laboratories: Research Funding.

Disease Characteristics and Patterns of Care In Elderly Patients (80+ years) with Follicular Lymphoma (FL) In the United States (US); Are Older Patients Treated Differently? Report From the National LymphoCare Study (NLCS)

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4152-4152
Author(s):  
Chadi Nabhan ◽  
Michelle Byrtek ◽  
Michael Taylor ◽  
Jill Tydell ◽  
Jamie H. Hirata ◽  
...  
Keyword(s):  
Older Patients ◽  
Research Funding ◽  
Age Groups ◽  
Treatment Patterns ◽  
Disease Stage ◽  
Younger Patients ◽  
Disease Characteristics ◽  
Significant Difference ◽  
The Difference ◽  
Grade 3

Abstract Abstract 4152 Background: While FL is the most common low-grade lymphoma in the US, median age was less than 60 in patients enrolled on pivotal studies that led to our understanding of disease biology and optimal therapy. It remains unclear whether similar disease characteristics, presentation, prognostic factors, treatment patterns, and outcomes pertain to older patients with FL. No clear guidelines exist on how older patients should be treated and data is lacking as to whether current practice patterns affect their survival and progression. Previous reports on FL in the elderly have been retrospective and single center-based. Methods: The NLCS is a prospective, longitudinal multicenter, observational study that enrolled consecutive newly diagnosed FL patients from 3/2004 through 3/2007 collecting data on disease and patients' characteristics, treatment patterns, and outcome. Using the NLCS data we analyzed information on disease stage, grade, FL International Prognostic Index (FLIPI), B symptoms, and treatment choice for patients <60 years, 60–69 years, 70–79 years, and 80+ years. Either Chi-square or Fisher's exact comparison was used to assess the correlations depending on the sample size of the test. Results: A total of 2,736 pts were enrolled, of which 1,215 (44%) were < 60, 708 (25%) were between 60–69, 549 (20%) were between 70–79, and 264 (9%) were >80. There was a significant difference in grade distribution across the different age groups (p < 0.0001), with 22% of pts 80+ having grade 3 FL vs 17% pts <60. No significant differences across age groups in B symptoms, extra nodal sites, or LDH values were observed. A significant difference in FLIPI score was seen across the age groups (p < 0.0001) where high-score FLIPI was present in 48% of pts 80+ as opposed to 16% of pts <60, although calculating FLIPI might be confounded by the fact that older patients were more likely to not have received a bone marrow (BM) exam with 66% of pts 80+ not having BM exam vs. only 40% of those <60 (p < 0.0001). The difference in FLIPI was mainly due to lower Hgb values as older patients were more likely to have had Hgb < 12 g/dL than younger patients (31% of pts 80+ vs. 15% of pts <60) and to age being a component of the FLIPI index. The difference in FLIPI score across age groups was also observed in patients with grade 3 FL where 53% of pts 80+ had poor FLIPI vs. 15% of pts <60 (p < 0.0001). A statistically significant difference in treatment patterns was found across age groups (p <0.0001). When treatment was implemented, older patients were more likely to have received rituximab (R) monotherapy (37% of 80+ vs. 12% of <60) and less likely to have received R+Chemotherapy (40% of pts 80+ vs. 64% of pts<60). In addition, more pts 80+ were observed compared to those <60 (23% vs. 16%). These differences persisted even in those with advanced stage (III/IV), grade 3 disease, region of diagnosis, and in poor-risk FLIPI. When chemotherapy was used, older patients were less likely than younger patients to receive anthracyclines (p < 0.0001) (31% of pts 80+ vs. 69% of pts<60). Anthracycline use remained significantly different regardless of disease stage, grade, or FLIPI score. Conclusions: To our knowledge, this is the largest prospective data collection available for FL pts 80+ years of age. We demonstrate that these pts have higher FLIPI score and grade 3 disease. When treatment is initiated, these patients receive R monotherapy more often than their younger counterpart. Anthracycline use in this population is also less common regardless of disease stage, grade, or risk profile. Whether these baseline differences translate into different outcomes remains to be seen. Disclosures: Nabhan: genentech: Research Funding, Speakers Bureau. Byrtek:Genentech: Employment. Taylor:Genentech: Employment. Hirata:Genentech: Employment. Flowers:Genentech/Biogen-Idec (unpaid): Consultancy; Celgene, Intellikine: Consultancy; Millennium: Research Funding.

Evaluation of the Clinical Features of 81 Patients with COVID-19: An Unpredictable Disease in Children

2020 ◽  
Author(s):  
Hayrettin Temel ◽  
Mehmet Gündüz ◽  
Hüseyin Arslan ◽  
Füsun Ünal ◽  
Emine Atağ ◽  
...  
Keyword(s):  
Clinical Features ◽  
Pediatric Patients ◽  
Clinical Laboratory ◽  
Tertiary Care ◽  
Age Groups ◽  
Signs And Symptoms ◽  
Asymptomatic Infection ◽  
Care Hospital ◽  
Significant Difference ◽  
History Of

Abstract Objective Data on the prognosis of clinical features of pediatric patients affected by the coronavirus disease 2019 (COVID-19) pandemic is insufficient. This study aimed to examine the clinical, laboratory, and radiology findings of pediatric patients diagnosed with COVID-19. Methods A total of 81 pediatric patients with a confirmed diagnosis of COVID-19 who were admitted to the pediatric clinics of our tertiary care hospital in Istanbul between March 22 and May 1, 2020, were included in the study. Results Of the patients, 40 (49.6%) were boys and 41 (50.6%) were girls. The mean age of the patients was 9.3 ± 5.5 years (range: 1 month–16 years). The most common symptoms were cough (28.4%) and fever (25.9%). A total of 26 patients (32.1%) had pharyngeal erythema. There was no significant difference between age groups in terms of symptoms, findings, clinical picture, history of contact, and clinical course (p > 0.001 for each). Abnormal findings were observed in seven (8.6%) patients on chest X-ray, and in four patients (4.9%) on thorax computed tomography. Only three of the patients were hospitalized and all of them discharged with healing. Conclusion The present study is the most comprehensive study on children diagnosed with COVID-19 in our country, which showed that the COVID-19 picture was mild in pediatric patients, but the signs and symptoms in children were not specific to the disease. Our findings also showed that the rate of asymptomatic infection in children was high and that it was difficult to recognize COVID-19 in children.

scholarly journals Age-Related Differences in the Informational Experiences and Needs of Patients with Lymphoma: Results from the 2020 Lymphoma Coalition Global Patient Survey

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 1929-1929
Author(s):  
Olufunmilayo A Bamigbola ◽  
Lorna E Warwick
Keyword(s):  
Information Needs ◽  
Medical Information ◽  
Age Groups ◽  
Older Age ◽  
Age Group ◽  
Younger Patients ◽  
Amount Of Information ◽  
Age Related ◽  
Younger Age ◽  
Significant Difference

Abstract Background Lymphomas can occur in all age groups but most commonly occur in older adults. Despite the shift towards patient- centered care, very little has been done to explore the information needs of patients with lymphoma by age. It is important for information to accessible to patients of all ages, as informed patients are consistently associated with better outcomes and healthcare experiences. In this study, Lymphoma Coalition (LC) describes the age-related differences in the information needs of patients with lymphoma using the 2020 LC Global Patient Survey (GPS). The objectives of this study were to identify: 1) how patients felt about the amount of information they received at diagnosis 2) the content of the information received at diagnosis and the level of understanding, and 3) their informational needs. Methods Globally, 11,878 respondents including 9,179 patients and 2,699 caregivers took part in the 2020 LC GPS. There were 9,078 patients included in this analysis who self-identified their age. These patients were grouped into five age groups for analysis: 18-29 (n=638), 30-39 (n=1,196), 40-59 (n=3,261), 60-69 (n=2,216), and 70+ (n=1,767). Demographics of the five age groups were examined, and descriptive analyses for all questions relating to information needs were performed in IBM SPSS v27. Results The five age groups differed significantly (p&lt; 0.001) in all the demographic categories examined. These categories included lymphoma subtype, sex, area of residence, education level, employment status, and household status. Patients were asked how they felt about the amount of information given to them at diagnosis. The oldest age group (70+) reported the highest prevalence (70%) of having received the right amount of information (Table 1). The younger age groups (18-29; 30-39; and 40-59) reported the highest prevalence of not receiving enough information (38%, 42%, and 41% respectively). Although not many patients reported being given too much information, of those who did, the younger age groups (18-29; 30-39; and 40-59) were the most prevalent (10%; 7%; and 5% respectively) (Table 1). Patients were asked about the type of information given to them at diagnosis, and how well they understood it. Compared to the younger age groups, the older age groups (60-69 and 70+) more frequently reported that they received and understood information given to them on different medical treatment options, the process and stages of their care, and how to manage side effects of treatment (Table 1). Patients were also asked what they needed more information about (Table 1). The top three areas that all patients needed more information about (regardless of age group) were treatment options, side effects from treatment, and their diagnosis and what it means. There was significant difference in the prevalence of how these information needs were reported between the age groups (Table 1). There was also significant difference in the prevalence of reporting a need for more information on support for self care, psychological support/counselling, and fertility across the age categories (Table 1). The lowest prevalence for needing more information in any of these areas was observed in the older age groups (60-69 and 70+), while the highest prevalence was observed in the youngest age groups (18-29 and 30-39) (Table 1). Although few patients reported not needing more information in any of these areas, its reporting was most prevalent in the older age groups (60-69 and 70+) (12% and 19%, respectively) (Table 1). Summary/Conclusions This analysis revealed that patients with lymphoma/CLL experience medical information differently across age groups. Compared to the mid and oldest patient groups, younger patients with lymphoma or CLL reported experiencing medical information differently than older patients do and reported less understanding of the medical information given to them. The younger patients also reported higher informational needs about their disease and treatment that may also be related to their age (e.g. information on fertility and family support). Clinicians should note these differences in age-group experiences and information needs, with the understanding that younger patients with lymphoma or CLL may require additional information, attention, and support. In the future, LC would like to explore how demographic differences may have confounded results. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

scholarly journals Bullying and Being Bullied; How Much Can It Increase the Risk of Depression and Anxiety in Students? A Multilevel Fixed-effect Model Analysis

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Ebrahim Babaee ◽  
Marzieh Nojomi ◽  
Mehran Asadi-Aliabadi ◽  
Babak Eshrati
Keyword(s):  
Age Groups ◽  
Well Being ◽  
Fixed Effect Model ◽  
Fixed Effect ◽  
Anxiety And Depression ◽  
Age Group ◽  
Depression And Anxiety ◽  
Odds Ratios ◽  
Effect Model ◽  
Significant Difference

Background: School violence as a health issue is a global concern. One of the problems that affect the health and well-being of children at school is bullying. Objectives: In this study, we aimed to examine the association of depression and anxiety with bullying among 6 - 19-year-old students in Iran. Methods: This study was conducted in Tehran, Iran, in 2020. A multistage cluster sampling method was used, and 54,550 students aged six to 19 years of both sexes, from urban and rural areas, were selected. Standard questionnaires, according to the WHO recommendations, were used for data collection. Involvement in bullying in the past 12 months and anxiety and depression status in both bully and bullied students were investigated by standard questionnaires. To compare the psychiatric problems and violent behavior, the Wald chi-square test was applied. The multilevel fixed-effect model and logistic multivariate regression were used to adjust the multilevel effects and estimate the odds of anxiety and depression in both bully and bullied students. All statistical analyses were performed at a 95% significance level. Results: Of the total students, 50.9% were males, 29.45% were in the 6 - 10 age group, and 70.55% in the 11 - 19 age group. There was a significant difference in depression and anxiety between boys and girls in both age groups (P < 0.001). Amongst males, 11.7% of the students aged 6 - 10 and 11% of the students aged 11 - 19 and in females, 7.7% aged 6 - 10 and 10.4% aged 11 - 19 had at least four experiences of bullying to others in the last year. The odds ratios for depression in male bullies were 1.3 and 1.5 in 6 - 10 and 11 - 19 age groups, respectively. The odds ratios for depression in bullied males and females were 4.2 and 3.9 in 6 - 10 and 2.9 and 4.3 in 11 - 19 age groups, respectively. Bulling others increased the odds of anxiety to 1.7 and 1.9 in males and 2.1 and 1.9 in females in 6 - 10 and 11 - 19 age groups, respectively. In bullied students, the odds of anxiety were estimated at 2.9 and 2.2 in males and 3.4 and 2.2 in female students respectively, in 6 - 10 and 11 - 19 age groups. Conclusions: There was a significant positive association between psychological disorders (anxiety and depression) and bullying among 6 - 19-year-old students. Victims of bullying were more at risk of depression and anxiety. This health-threatening phenomenon should not be ignored.

scholarly journals Evaluation of Drug Utilisation Pattern and Clinical Presentation in Covid19 Patients Based on the Disease Severity

2021 ◽  
Vol 11 (2) ◽  
pp. 25-33
Author(s):  
Kamsali Hema ◽  
Peddoju Moulika ◽  
Dinesh Kumar Kukunuri ◽  
Ganta Saidhulu ◽  
Dhivya K ◽  
...  
Keyword(s):  
Clinical Features ◽  
Communicable Disease ◽  
Age Groups ◽  
The Elderly ◽  
Viral Disease ◽  
Severe Illness ◽  
Laboratory Findings ◽  
Clinical Presentations ◽  
Significant Difference ◽  
Study Population

Coronavirus disease of 2019 (COVID-19) is an extremely communicable disease characterized by the serious acute respiratory influenza virus 2, a recently identified novel viral disease (SARS-CoV-2). Hitherto, the quantity of established instances worldwide has reached 135 million, and the number of deaths is 2.9 million. In India, the cases were found to be 20 million and the mortality rate is 3,51,000. This virus was first identified in Wuhan City, Hubei Province in China, at the end of 2019. Until now, it affected more than 200 countries. The treatment pattern and clinical presentations were assessed in COVID 19 patients. A total of 146 patients, severe patients (n = 71) and non-severe patients (n = 75) where included in the study. The mean age of the study population was found to be 58.76±14.32 and the most common symptoms of patients include fever, fatigue, dry cough, and diarrhea there is no statistically significant difference in the clinical features between severe and non-severe patients. There is no significant difference in the laboratory findings except lymphocyte count, CORADS and N/L ratio between severe and non-severe patients. COVID-19 affects all age groups especially the elderly. The risk for severe illness with COVID-19 increases with age. COVID 19 patients were presented with various the risk factors and the clinical features in the severe and non severe conditions patients, our study shows great significance to prevent the patient turning to critical condition during diagnosis and treatment.

scholarly journals Depression and anxiety in a case series of amyotrophic lateral sclerosis: frequency and association with clinical features

2017 ◽  
Vol 15 (1) ◽  
pp. 58-60 ◽  
Author(s):  
Laura de Godoy Rousseff Prado ◽  
Isabella Carolina Santos Bicalho ◽  
Mauro Vidigal-Lopes ◽  
Vitor de Godoy Rousseff Prado ◽  
Rodrigo Santiago Gomez ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Depressive Symptoms ◽  
Clinical Features ◽  
Disease Duration ◽  
Age At Onset ◽  
Anxiety And Depression ◽  
Functional Score ◽  
Significant Difference ◽  
Clinically Significant ◽  
Lateral Sclerosis

ABSTRACT Objective To investigate the frequency of anxiety and depression and their association with clinical features of amyotrophic lateral sclerosis. Methods This is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to Awaji’s criteria. Patients underwent clinical and psychiatric assessment (anxiety and depression symptoms). Results We included 76 patients. The men/women ratio was 1.6:1. Participants’ mean age at disease onset was 55 years (SD±12.1). Sixty-six patients (86.8%) were able to complete psychiatric evaluation. Clinically significant anxiety was found in 23 patients (34.8%) while clinically significant depression was found in 24 patients (36.4%). When we compared patients with and without depression a significant difference was seen only in the frequency of anxiety symptoms (p<0.001). We did further analysis comparing subgroups of patients classified according to the presence or not of anxiety and or depression, without any significant difference regarding sex, age at onset, initial form, disease duration or functional measures. A positive correlation between anxiety and depressive symptoms was found (p<0.001). Conclusion Anxiety and depressive symptoms were highly correlated and frequent in patients with amyotrophic lateral sclerosis. In addition, anxiety and depression were not associated with disease duration and presentation, sex, age at onset, and functional score.

Sign in / Sign up

Export Citation Format

Share Document